EP: 4. Treatment Landscape Surrounding Atopic Dermatitis EP: 5. Topical vs Systemic Treatment for AD EP: 6. Typical Onset of Action to Relieve Itch Associated with Atopic Dermatitis EP: 7.

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat immune ...

LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting ...

Casey Butrus, PharmD: Dr Cameron, describe different presentations of atopic dermatitis and how the management strategies differ for each presentation. Michael Cameron, MD, FAAD: In the pediatric ...

Genetic biomarkers for atopic dermatitis (AD) vary from one ethnic group to another, with a mutation in the interleukin-17 receptor A (IL-17RA) gene particularly important in Korean patients ...

Atopic dermatitis is a common disease, and new ways of treating it are needed. More detailed research into the genetic loci we have now identified may lead to the development of novel therapies in ...

The use of ruxolitinib 1.5% cream, which was approved in 2021 for short-term and noncontinuous chronic treatment of mild-to-moderate atopic dermatitis in patients age 12 and older, is strongly ...

How an unbalanced skin microbiome worsens atopic dermatitis The complex community of microorganisms that live on the skin is often out of balance in people with atopic dermatitis (AD).

Based on the SCORing Atopic Dermatitis (SCORAD) test, Eczema Area and Severity Index (EASI) and affected body surface area, male patients had more objective severe symptoms than female patients.

Anywhere from 20 to 80 percent of people with atopic dermatitis have food allergies, with milk, peanuts, eggs, soy, wheat, seafood, and shellfish being the most common allergens triggering AD ...